| [1] |
Horst Sievert. 结构性心脏病介入治疗:现在和未来[J]. 中华医学信息导报, 2015,0(16):14.
|
| [2] |
葛均波. 结构性心脏病的定义、范畴及其现状和未来[J]. 上海医学, 2021, 44(4):217-220.
|
| [3] |
Rashkind WJ, Miller WW. Creation of an atrial septal defect without thoracotomy. A palliative approach to complete transposition of the great arteries[J]. JAMA, 1966, 196(11):991-992.
|
| [4] |
Porstmann W, Wierny L, Warnke H, et al. Catheter closure of patent ductus arteriosus. 62 cases treated without thoracotomy[J]. Radiol Clin North Am, 1971,9(2):203-218.
|
| [5] |
钱明阳. 先天性心脏病介入治疗的现状与争议[J]. 岭南心血管病杂志, 2010, 16(6):437-440,448.
|
| [6] |
周爱卿, 王荣发, 高伟, 等. 复杂性先天性心脏病的介入治疗[J]. 中华儿科杂志, 2004, 42(11):813-816.
|
| [7] |
戴汝平. 开拓介入治疗新领域——先天性心脏病的介入治疗[J]. 中华心血管病杂志, 2000, 28(2):85.
|
| [8] |
朱鲜阳, 韩秀敏, 全薇, 等. 肌部室间隔缺损封堵治疗成功2例报告[J]. 沈阳部队医药, 2002, (3):229-230,266.
|
| [9] |
秦永文, 赵仙先, 徐荣良, 等. 应用自制封堵器经导管闭合膜部室间隔缺损[J]. 中华心血管病杂志, 2003, 31(1):28-28.
|
| [10] |
中华儿科杂志编辑委员会, «中华医学杂志英文版»编辑委员. 先天性心脏病经导管介入治疗指南[J]. 中华儿科杂志, 2004, 42(3):234-239.
|
| [11] |
国家卫生健康委员会国家结构性心脏病介入质量控制中心, 国家心血管病中心结构性心脏病介入质量控制中心, 中华医学会心血管病学分会先心病经皮介入治疗指南工作组, 等. 常见先天性心脏病经皮介入治疗指南(2021版)[J]. 中华医学杂志, 2021, 101(38):3054-3076.
|
| [12] |
Humenberger M, Rosenhek R, Gabriel H, et al. Benefit of atrial septal defect closure in adults: impact of age[J]. Eur Heart J, 2011, 32(5):553-560.
|
| [13] |
Zhang X, Chen S, Li W, et al. A novel puncturable atrial septal defect occluder: The results of preclinical experiment and first-in-human study[J]. JACC Basic Transl Sci, 2022, 7(12):1200-1210.
|
| [14] |
Homma S, Messé SR, Rundek T, et al. Patent foramen ovale[J]. Nat Rev Dis Primers, 2016, 2:15086.
|
| [15] |
Rundek T, Elkind MS, Di Tullio MR, et al. Patent foramen ovale and migraine: a cross-sectional study from the Northern Manhattan Study (NOMAS)[J]. Circulation, 2008,118(14):1419-1424.
|
| [16] |
Mojadidi MK, Zaman MO, Elgendy IY, et al. Cryptogenic stroke and patent foramen ovale[J]. J Am Coll Cardiol, 2018, 71(9):1035-1043.
|
| [17] |
Mas J L, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke[J]. N Engl J Med, 2017,377(11):1011-1021.
|
| [18] |
Søndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke[J]. N Engl J Med, 2017, 377(11):1033-1042.
|
| [19] |
Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke[J]. N Engl J Med, 2017, 377(11):1022-1032.
|
| [20] |
Lee PH, Song JK, Kim JS, et al. Cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE-PFO trial[J]. J Am Coll Cardiol, 2018, 71(20):2335-2342.
|
| [21] |
张玉顺, 蒋世良, 朱鲜阳. 卵圆孔未闭相关卒中预防中国专家指南[J]. 心脏杂志, 2021, 33(1):1-10.
|
| [22] |
Mullen MJ, Hildick-Smith D, De Giovanni JV, et al. BioSTAR Evaluation STudy (BEST): a prospective, multicenter, phase I clinical trial to evaluate the feasibility, efficacy, and safety of the BioSTAR bioabsorbable septal repair implant for the closure of atrial-level shunts[J]. Circulation, 2006, 114(18):1962-1967.
|
| [23] |
Miyake T, Shinohara T, Fukuda T, et al. Spontaneous closure of perimembranous ventricular septal defect after school age[J]. Pediatr Int, 2008, 50(5):632-635.
|
| [24] |
Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease[J]. Eur Heart J, 2021, 42(6):563-645.
|
| [25] |
Cribier A. Invention and uptake of TAVI over the first 20 years[J]. Nat Rev Cardiol, 2022, 19(7):427-428.
|
| [26] |
葛均波, 周达新, 潘文志, 等. 经皮主动脉瓣植入术一例及其操作要点[J]. 中国介入心脏病学杂志, 2010, 18(5):243-246.
|
| [27] |
Otto C M, Nishimura R A, Bonow R O, et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J]. Circulation, 2021,143(5):e72-e227.
|
| [28] |
Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)[J]. Rev Esp Cardiol (Engl Ed), 2022,75(6):524.
|
| [29] |
中国医师协会心血管内科医师分会结构性心脏病专业委员会. 中国经导管主动脉瓣置换术临床路径专家共识(2021版)[J]. 中国循环杂志, 2022, 37(1):12-23.
|
| [30] |
Eltchaninoff H, Durand E, Avinée G, et al. Assessment of structural valve deterioration of transcatheter aortic bioprosthetic balloon-expandable valves using the new European consensus definition[J]. EuroIntervention, 2018, 14(3):e264-e271.
|
| [31] |
Jorgensen T H, Thyregod H, Ihlemann N, et al. Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement[J]. Eur Heart J, 2021,42(30):2912-2919.
|
| [32] |
O'Hair D, Yakubov SJ, Grubb KJ, et al. Structural valve deterioration after self-expanding transcatheter or surgical aortic valve implantation in patients at intermediate or high risk[J]. JAMA Cardiol, 2023, 8(2):111-119.
|
| [33] |
Ge J, Zhou D, Zhang X, et al. Preliminary implantation of a novel TAVR device with polymeric leaflets for symptomatic calcific aortic disease[J]. JACC Case Rep, 2023, 17:101901.
|
| [34] |
Kapadia SR, Makkar R, Leon M, et al. Cerebral embolic protection during transcatheter aortic-valve replacement[J]. N Engl J Med, 2022, 387(14):1253-1263.
|
| [35] |
Flint N, Wunderlich NC, Shmueli H, et al. Aortic regurgitation[J]. Curr Cardiol Rep, 2019, 21(7):65.
|
| [36] |
Takagi H, Hari Y, Kawai N, et al. Meta-analysis and meta-regression of transcatheter aortic valve implantation for pure native aortic regurgitation[J]. Heart Lung Circ, 2020, 29(5):729-741.
|
| [37] |
Zhu D, Hu J, Meng W, et al. Successful transcatheter aortic valve implantation for pure aortic regurgitation using a new second generation self-expanding J-Valve(TM) system - the first in-man implantation[J]. Heart Lung Circ, 2015, 24(4):411-414.
|
| [38] |
Yokoyama H, Tamm AR, Geyer M, et al. Treatment of severe aortic valve regurgitation with the Trilogy TAVI system[J]. EuroIntervention, 2023, 18(17):1444-1445.
|
| [39] |
中国医师协会心血管内科医师分会结构性心脏病专业委员会. 经导管主动脉瓣置换术中国专家共识(2020更新版)[J]. 中国介入心脏病学杂志, 2020, 28(6):301-309.
|
| [40] |
Perlman GY, Blanke P, Dvir D, et al. Bicuspid aortic valve stenosis: favorable early outcomes with a next-generation transcatheter heart valve in a multicenter study[J]. JACC Cardiovasc Interv, 2016, 9(8):817-824.
|
| [41] |
Yoon SH, Lefèvre T, Ahn JM, et al. Transcatheter aortic valve replacement with early- and new-generation devices in bicuspid aortic valve stenosis[J]. J Am Coll Cardiol, 2016, 68(11):1195-1205.
|
| [42] |
Yoon SH, Kim WK, Dhoble A, et al. Bicuspid aortic valve morphology and outcomes after transcatheter aortic valve replacement[J]. J Am Coll Cardiol, 2020, 76(9):1018-1030.
|
| [43] |
Jin Q, Chen S, Yang X, et al. Clinical outcomes of bicuspid versus tricuspid aortic valve stenosis after transcatheter aortic valve replacement with self-expandable valves[J]. BMC Cardiovasc Disord, 2022, 22(1):540.
|
| [44] |
Xiong TY, Ali WB, Feng Y, et al. Transcatheter aortic valve implantation in patients with bicuspid valve morphology: a roadmap towards standardization[J]. Nat Rev Cardiol, 2023, 20(1):52-67.
|
| [45] |
Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study[J]. Lancet, 2006, 368(9540):1005-1011.
|
| [46] |
Mack MJ, Lindenfeld J, Abraham WT, et al. 3-year outcomes of transcatheter mitral valve repair in patients with heart failure[J]. J Am Coll Cardiol, 2021, 77(8):1029-1040.
|
| [47] |
Bonow RO, O'Gara P , Adams DH, et al. 2020 focused update of the 2017 ACC expert consensus decision pathway on the management of mitral regurgitation: A report of the American College of Cardiology Solution Set Oversight Committee[J]. J Am Coll Cardiol, 2020,75(17):2236-2270.
|
| [48] |
中华医学会心血管病学分会. 经导管二尖瓣缘对缘修复术的中国专家共识[J]. 中华心血管病杂志, 2022, 50(9):853-863.
|
| [49] |
von Bardeleben RS, Rogers JH, Mahoney P, et al. Real-world outcomes of fourth-generation mitral transcatheter repair: 30-day results from EXPAND G4[J]. JACC Cardiovasc Interv, 2023, 16(12):1463-1473.
|
| [50] |
Lim DS, Smith RL, Gillam LD, et al. Randomized comparison of transcatheter edge-to-edge repair for degenerative mitral regurgitation in prohibitive surgical risk patients[J]. JACC Cardiovasc Interv, 2022, 15(24):2523-2536.
|
| [51] |
De Bonis M, Al-Attar N, Antunes M, et al. Surgical and interventional management of mitral valve regurgitation: a position statement from the European Society of Cardiology Working Groups on Cardiovascular Surgery and Valvular Heart Disease[J]. Eur Heart J, 2016,37(2):133-139.
|
| [52] |
Messika-Zeitoun D, Nickenig G, Latib A, et al. Transcatheter mitral valve repair for functional mitral regurgitation using the Cardioband system: 1 year outcomes[J]. Eur Heart J, 2019, 40(5):466-472.
|
| [53] |
郭潇雅. "DragonRing"亮相华西医院[J]. 中国医院院长, 2023, (2):20-21.
|
| [54] |
Latib A, Ho EC, Scotti A, et al. First-in-human transseptal transcatheter mitral chordal repair[J]. JACC Cardiovasc Interv, 2022, 15(17):1768-1769.
|
| [55] |
Gammie JS, Bartus K, Gackowski A, et al. Beating-heart mitral valve repair using a novel ePTFE cordal implantation device: A prospective trial[J]. J Am Coll Cardiol, 2018, 71(1):25-36.
|
| [56] |
Li W, Long Y, Pan W, et al. Transcatheter edge to edge repair using the ease-of-use valve clamp system for functional mitral regurgitation: a primary report[J]. Surg Today, 2023, 53(1):90-97.
|
| [57] |
Zahr F, Song HK, Chadderdon SM, et al. 30-Day outcomes following transfemoral transseptal transcatheter mitral valve replacement: intrepid TMVR early feasibility study results[J]. JACC Cardiovasc Interv, 2022, 15(1):80-89.
|
| [58] |
Zahr F, Song H K, Chadderdon S, et al. 1-Year outcomes following transfemoral transseptal transcatheter mitral valve replacement: intrepid TMVR Early Feasibility Study Results[J]. JACC Cardiovasc Interv, 2023, 10: S1936-8798(23)01357-2.
|
| [59] |
Eleid MF, Wang DD, Pursnani A, et al. 2-year outcomes of transcatheter mitral valve replacement in patients with annular calcification, rings, and bioprostheses[J]. J Am Coll Cardiol, 2022, 80(23):2171-2183.
|
| [60] |
中国医师协会超声分会超声心动图专业委员会, 中国医师协会心血管内科医师分会结构性心脏病学组. 二尖瓣经导管缘对缘修复的超声心动图操作规范中国专家共识[J]. 中国介入心脏病学杂志, 2022, 30(10):721-733.
|
| [61] |
中华医学会心血管病学分会. 经导管二尖瓣缘对缘修复术的中国专家共识[J]. 中华心血管病杂志, 2022, 50(9):853-863.
|
| [62] |
Lurz P, Besler C, Schmitz T, et al. Short-term outcomes of tricuspid edge-to-edge repair in clinical practice[J]. J Am Coll Cardiol, 2023, 82(4):281-291.
|
| [63] |
Kodali SK, Hahn RT, Davidson CJ, et al. 1-Year outcomes of transcatheter tricuspid valve repair[J]. J Am Coll Cardiol, 2023, 81(18):1766-1776.
|
| [64] |
Gray WA, Abramson SV, Lim S, et al. 1-Year outcomes of cardioband tricuspid valve reconstruction system early feasibility study[J]. JACC Cardiovasc Interv, 2022, 15(19):1921-1932.
|
| [65] |
龙愉良, 潘文志, 陈莎莎,等. 运用K-Clip~(TM)行经导管三尖瓣环成形术1例[J]. 中华心血管病杂志, 2023, 51(2):188-190.
|
| [66] |
Webb JG, Chuang AM, Meier D, et al. Transcatheter tricuspid valve replacement with the EVOQUE system: 1-year outcomes of a multicenter, first-in-human experience[J]. JACC Cardiovasc Interv, 2022, 15(5):481-491.
|
| [67] |
Stolz L, Weckbach LT, Hahn RT, et al. 2-year outcomes following transcatheter tricuspid valve replacement using the EVOQUE system[J]. J Am Coll Cardiol, 2023, 81(24):2374-2376.
|
| [68] |
Blusztein DI, Hahn RT, Godoy Rivas C, et al. Transcatheter tricuspid valve replacement with novel self-expanding valve: secure fixation in insecure anatomy[J]. JACC Case Rep, 2023, 12:101773.
|
| [69] |
Ou-Yang WB, Qureshi S, Ge JB, et al. Multicenter comparison of percutaneous and surgical pulmonary valve replacement in large RVOT[J]. Ann Thorac Surg, 2020, 110(3):980-987.
|
| [70] |
Sivakumar K, Sagar P, Qureshi S, et al. Outcomes of Venus P-valve for dysfunctional right ventricular outflow tracts from Indian Venus P-valve database[J]. Ann Pediatr Cardiol, 2021, 14(3):281-292.
|
| [71] |
Osmancik P, Herman D, Neuzil P, et al. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation[J]. J Am Coll Cardiol, 2020, 75(25):3122-3135.
|
| [72] |
Osmancik P, Herman D, Neuzil P, et al. 4-Year outcomes after left atrial appendage closure versus nonwarfarin oral anticoagulation for atrial fibrillation[J]. J Am Coll Cardiol, 2022, 79(1):1-14.
|
| [73] |
Lakkireddy D, Thaler D, Ellis CR, et al. Amplatzer amulet left atrial appendage occluder versus Watchman device for stroke prophylaxis (Amulet IDE): a randomized, controlled trial[J]. Circulation, 2021, 144(19):1543-1552.
|
| [74] |
Price MJ, Friedman DJ, Du C, et al. Comparative safety of transcatheter LAAO with the first-generation Watchman and next-generation Watchman FLX devices[J]. JACC Cardiovasc Interv, 2022, 15(21):2115-2123.
|
| [75] |
蒲俊舟, 吴文辉, 科雨彤, 等. 心脏瓣膜替换术后瓣周漏的介入与外科治疗的比较观察[J]. 中华医学杂志, 2021, 101(16):1160-1164.
|
| [76] |
Wang Z, Zhao R, Sievert H, et al. First-in-man application of Liwen RF™ ablation system in the treatment of drug-resistant hypertrophic obstructive cardiomyopathy[J]. Front Cardiovasc Med, 2022, 9:1028763.
|